Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease. The Company's lead product candidate, AKB-6548, is being developed as a once-daily, oral therapy. It has completed a Phase IIb study demonstrating that AKB-6548 can raise hemoglobin levels in non-dialysis patients with anemia related to chronic kidney disease (CKD). The Company is also conducting a Phase II study for the treatment of anemia in patients undergoing dialysis. The Company's preclinical candidate, AKB-6899, is a small molecule with minor structural differences from its lead compound AKB-6548. AKB-6899 is being developed for the treatment of certain cancers.